HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma



The College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline that addresses appropriate testing of HER2/neu status in patients with gastric and gastroesophageal (GEA) cancers.

Titled "CAP-ASCP-ASCO HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline," this evidence-based guidance is now available as an early online release published in Archives of Pathology & Laboratory Medicine, American Journal of Clinical Pathology, and the Journal of Clinical Oncology.

The overarching questions that the guideline development panel of experts addressed were:

  1. What is the optimal testing algorithm to assess HER2 status in patients with GEA?
  2. What strategies can help ensure optimal performance, interpretation, and reporting of established assays in patients with GEA?

The guideline includes 11 recommendations to address opportunities for improving patient outcomes. Recommendations are separated to support those who perform tumor tissue testing as well as those who treat the patient. By addressing elements across the patient care continuum, this evidence-based guideline will help establish standard HER2 testing, improve the accuracy of the test interpretation, guide HER2-targeted therapies, and provide accurate, personalized care for gastric cancer patients.

Guideline Resources

Download the following:

CAP-ASCP-ASCO HER2 Testing and Clinical Decision-making in Gastroesophageal Adenocarcinoma Guideline


Question or Comment?


Guideline status: Active

Update published online ahead of print: November 14, 2016

Originally published: December 2016